(9ci)-2-(3-甲基丁基)-1H-苯并咪唑 | 946-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-2-(3-甲基丁基)-1H-苯并咪唑
• 英文名称: 2-Isopentyl-benzimidazol
• 英文别名: 2-(3-Methylbutyl)-1H-benzimidazole
• CAS: 946-18-9
• 化学式: C₁₂H₁₆N₂
• 分子量: 188.272
• InChiKey: WZJCXUYUKDHVTK-UHFFFAOYSA-N

物化性质

• 沸点：
  361.5±11.0 °C(Predicted)
• 密度：
  1.058±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-溴甲基-7,8-二氟-2(1H)-喹啉酮 、 (9ci)-2-(3-甲基丁基)-1H-苯并咪唑 生成 7,8-difluoro-4-((2-isopentyl-1H-benzo[d]imidazol-1-yl)methyl)-quinolin-2(1H)-one
  参考文献：
  名称：

  QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS

  摘要：

  本发明涉及式I的新型喹诺酮，其抑制可诱导型一氧化氮合酶，以及合成和使用该化合物的方法，包括通过给予该化合物治疗疾病的方法，用于抑制或调节一氧化氮合成和/或降低患者体内一氧化氮水平。

  公开号：

  US20080139558A1
• 作为产物：
  描述：

  4-甲基戊酸 、 邻苯二胺 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 4.0h， 以57%的产率得到(9ci)-2-(3-甲基丁基)-1H-苯并咪唑
  参考文献：
  名称：

  Discovery of Dual Inducible/Neuronal Nitric Oxide Synthase (iNOS/nNOS) Inhibitor Development Candidate 4-((2-Cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) Part 2: Identification of a Novel, Potent, and Selective Series of Benzimidazole-Quinolinone iNOS/nNOS Dimerization Inhibitors That Are Orally Active in Pain Models

  摘要：

  Three isoforms of nitric oxide synthase (NOS), dimeric enzymes that catalyze the formation of nitric oxide (NO) from arginine, have been identified. Inappropriate or excessive NO produced by iNOS and/or nNOS is associated with inflammatory and neuropathic pain. Previously, we described the identification of a series of amide-quinolinone iNOS dimerization inhibitors that although potent, suffered from high clearance and limited exposure in vivo. By conformationally restricting the amide of this progenitor series, we describe the identification of a novel series of benzimidazole-quinolinone dual iNOS/nNOS inhibitors with low clearance and sustained exposure in vivo. Compounds were triaged utilizing an LPS challenge assay coupled with mouse and rhesus pharmacokinetics and led to the identification of 4,7-imidazopyrazine 42 as the lead compound. 42 (KD7332) (J. Med. Chem. 2009, 52, 3047-3062) was confirmed as an iNOS dimerization inhibitor and was efficacious in the mouse formalin model of nociception and Chung model of neuropathic pain, without showing tolerance after repeat dosing. Further 42 did not affect motor coordination up to doses or 1000 mg/kg, demonstrating a wide therapeutic margin.

  DOI：

  10.1021/jm100828n

文献信息

• Peripherally Acting Opioid Compounds
  申请人：Blumberg Laura Cook

  公开号：US20130005755A1

  公开（公告）日：2013-01-03

  The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:

  这项发明涉及公式I、II、III、IV的化合物，或其药学上可接受的酯或前药。
• BENZAZEPIN-2(1H)-ONE DERIVATIVES
  申请人：Boyle Jessica

  公开号：US20080103130A1

  公开（公告）日：2008-05-01

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.

  式(I)的化合物及其药用可接受的盐是β-2肾上腺素受体的激动剂。它们可用作家畜动物的饲料添加剂。
• Antimalarial Quinolines and Methods of Use Thereof
  申请人：Wolf Christian

  公开号：US20110045100A1

  公开（公告）日：2011-02-24

  One aspect of the invention relates to substitute quinolines with antimalarial activity, and compositions and kits comprising at least one of them. Another aspect of the invention relates to methods for the treatment or prevention or both of malaria comprising administering to a subject a therapeutically effective amount of such a compound. Importantly, a number of the compounds show excellent potency against both chloroquine-sensitive and chloroquine-resistant strains.

  本发明的一个方面涉及具有抗疟活性的替代喹啉，以及包含至少其中之一的组合物和试剂盒。另一个方面涉及用这种化合物向受试者施用治疗有效量的方法，以治疗或预防疟疾。重要的是，其中一些化合物对氯喹敏感和氯喹耐药菌株都表现出极高的效力。
• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：Shy Therapeutics LLC

  公开号：US11000515B2

  公开（公告）日：2021-05-11

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• Solderability assessment
  申请人：——

  公开号：US20020067486A1

  公开（公告）日：2002-06-06

  A method for assessing the solderability of metals by spectroscopy is provided. The method includes illuminating the sample and collecting and analyzing the spectral characteristics of the sample. Specifically, the present invention effectively solves the problem of evaluating the solderability of preservative coated metals. An apparatus and software are also provided which are in particular useful to assess the solderability of preservative coated metals.

  提供了一种通过光谱评估金属可焊性的方法。该方法包括照亮样品并收集和分析样品的光谱特征。具体来说，本发明有效地解决了评估防腐涂层金属可焊性的问题。本发明还提供了一种仪器和软件，特别适用于评估防腐涂层金属的可焊性。